AR096585A1 - Derivados de prodroga de triazolpiridinas sustituidas - Google Patents
Derivados de prodroga de triazolpiridinas sustituidasInfo
- Publication number
- AR096585A1 AR096585A1 ARP140102239A ARP140102239A AR096585A1 AR 096585 A1 AR096585 A1 AR 096585A1 AR P140102239 A ARP140102239 A AR P140102239A AR P140102239 A ARP140102239 A AR P140102239A AR 096585 A1 AR096585 A1 AR 096585A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- group selected
- hydrogen atom
- alkyl
- cr4r5
- Prior art date
Links
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Procesos para su preparación y son útiles como inhibidores de la Mps-1 quinasa. Reivindicación 1: Un compuesto de fórmula general (1), en donde: RA representa un grupo seleccionado entre: -C(=O)-(C₂₋₆-alquilen)-N(R³ᵃ)R³, -C(=O)-(CR⁴R⁵)-N(R⁶)R⁷, -C(=O)-O-(C₂₋₆-alquilen-N(R³ᵃ)R³, -C(=O)-O-(CR⁴R⁵)-O-P(=O)(OH)₂, -C(=O)-O-(CR⁴R⁵)-O-C(=O)-R⁸, -C(=O)-O-(CR⁴R⁵)-O-C(=O)-C(R⁶)(R⁶ᵃ)-NH-C(=O)-R⁹; R¹ representa un grupo seleccionado entre metoxi- y 2,2,2-trifluoroetoxi; R² representa un grupo seleccionado entre el grupo de fórmulas (2); donde * indica el punto de unión al anillo fenilo al que se une R²; R³ representa un grupo seleccionado entre: C₁₋₆-alquilo, C₃₋₆-cicloalquilo, heterocicloalquilo de entre 4 y 7 miembros; donde dicho grupo está opcionalmente sustituido, una o más veces, en forma idéntica o diferente, con un grupo seleccionado entre: -OH, -NH, -N(H)R¹⁰, -N(R¹⁰)R¹¹, -O-P(=O)(OH)₂; R³ᵃ representa un átomo de hidrógeno o un grupo C₁₋₃-alquilo; R⁴ y R⁵, en forma independiente entre sí, representan un grupo seleccionado entre un átomo de hidrógeno y un grupo C₁₋₆-alquilo, o R⁴ y R⁵, junto con el átomo de carbono al cual se encuentran unidos, forman un anillo C₃₋₆-cicloalquilo; R⁶ representa un átomo de hidrógeno o un grupo C₁₋₆-alquilo; R⁶ᵃ representa un átomo de hidrógeno o un grupo C₁₋₃-alquilo; R⁷ representa un átomo de hidrógeno o un grupo -C(=O)R⁹; R⁸ representa un grupo seleccionado entre: C₁₋₆-alquilo, C₃₋₆-cicloalquilo, heterocicloalquilo de entre 4 y 7 miembros; donde dicho grupo está opcionalmente sustituido, una o más veces, en forma idéntica o diferente, con un grupo seleccionado entre: -OH, -NH₂, -N(H)R¹⁰, -N(R¹⁰)R¹¹, -O-P(=O)(OH)₂; R⁹ representa un grupo de fórmula (3) donde ** indica el punto de unión al grupo carbonilo al que se une R⁹; R¹⁰ y R¹¹, en forma independiente entre sí, representan un grupo seleccionado entre un átomo de hidrógeno y un grupo C₁₋₃-alquilo, o R¹⁰ y R¹¹, junto con el átomo de nitrógeno al cual están unidos forman un anillo heterocicloalquilo de entre 4 y 7 miembros; R¹² representa un grupo seleccionado entre un átomo de hidrógeno, -OH, -NR¹⁰R¹¹, -NH-C(=NH)-NH₂; n es el entero 0, 1, 2, 3 ó 4; o un tautómero, un N-óxido, un hidrato, un solvato, o una sal del mismo, o una mezcla de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13171508 | 2013-06-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096585A1 true AR096585A1 (es) | 2016-01-20 |
Family
ID=48576905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102239A AR096585A1 (es) | 2013-06-11 | 2014-06-11 | Derivados de prodroga de triazolpiridinas sustituidas |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US9586958B2 (es) |
| EP (1) | EP3008062B1 (es) |
| JP (1) | JP2016526534A (es) |
| KR (1) | KR20160019492A (es) |
| CN (1) | CN105377848A (es) |
| AP (1) | AP2015008898A0 (es) |
| AR (1) | AR096585A1 (es) |
| AU (1) | AU2014280356A1 (es) |
| CA (1) | CA2914745A1 (es) |
| CL (1) | CL2015003605A1 (es) |
| CR (1) | CR20150659A (es) |
| CU (1) | CU20150176A7 (es) |
| DK (1) | DK3008062T3 (es) |
| DO (1) | DOP2015000299A (es) |
| EA (1) | EA201600002A1 (es) |
| ES (1) | ES2626790T3 (es) |
| HK (1) | HK1221955A1 (es) |
| HR (1) | HRP20170717T1 (es) |
| HU (1) | HUE033131T2 (es) |
| IL (1) | IL242847A0 (es) |
| LT (1) | LT3008062T (es) |
| MA (1) | MA38654B1 (es) |
| MX (1) | MX2015017119A (es) |
| NI (1) | NI201500176A (es) |
| PE (1) | PE20160156A1 (es) |
| PH (1) | PH12015502746A1 (es) |
| PL (1) | PL3008062T3 (es) |
| PT (1) | PT3008062T (es) |
| RS (1) | RS56034B1 (es) |
| SG (1) | SG11201509858QA (es) |
| SI (1) | SI3008062T1 (es) |
| TN (1) | TN2015000545A1 (es) |
| UY (1) | UY35610A (es) |
| WO (1) | WO2014198647A2 (es) |
| ZA (1) | ZA201508868B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41136A (fr) * | 2014-12-09 | 2017-10-17 | Bayer Pharma AG | Composés pour le traitement d'un cancer |
| EP3283642B1 (en) | 2015-04-17 | 2023-10-11 | Netherlands Translational Research Center Holding B.V. | Prognostic biomarkers for ttk inhibitor chemotherapy |
| JP7121722B2 (ja) | 2016-04-04 | 2022-08-18 | ケモセントリックス，インコーポレイティド | 可溶性Ｃ５ａＲアンタゴニスト |
| WO2023113478A1 (en) * | 2021-12-15 | 2023-06-22 | Sillajen, Inc. | Methods of treating neoplastic diseases |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9903965A3 (en) | 1996-08-28 | 2002-02-28 | Pfizer | Substituted 6,5-hetero-bicyclic derivatives |
| DK0991628T3 (da) | 1997-05-28 | 2005-05-17 | Aventis Pharma Inc | Quinolin- og quinoxalinforbindelser, der inhiberer blodpladeafledt vækstfaktor og/eller p561ck-tyrosin-kinaser |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| JP2004346016A (ja) | 2003-05-22 | 2004-12-09 | Otsuka Chemical Co Ltd | トリフルオロメチルキノキサリン化合物、その製造方法、及び有害生物防除剤 |
| WO2005030121A2 (en) | 2003-06-30 | 2005-04-07 | Hif Bio, Inc. | Compounds, compositions and methods |
| EP1799680A2 (en) | 2004-10-07 | 2007-06-27 | Warner-Lambert Company LLC | Triazolopyridine derivatives as antibacterial agents |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2007065010A2 (en) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| KR20090026288A (ko) | 2006-05-31 | 2009-03-12 | 갈라파고스 엔.브이. | 퇴행성 및 염증성 질환의 치료에 유용한 트리아졸로피라진 화합물 |
| AU2007284562B2 (en) | 2006-08-16 | 2013-05-02 | Exelixis, Inc. | Using PI3K and MEK modulators in treatments of cancer |
| CN103641829A (zh) | 2006-08-30 | 2014-03-19 | 塞尔佐姆有限公司 | 作为激酶抑制剂的三唑衍生物 |
| US7592342B2 (en) | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors |
| KR20100049073A (ko) | 2007-07-18 | 2010-05-11 | 노파르티스 아게 | 비시클릭 헤테로아릴 화합물 및 키나제 억제제로서의 그의 용도 |
| JP2010535804A (ja) | 2007-08-09 | 2010-11-25 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体 |
| MX2010002115A (es) | 2007-08-23 | 2010-06-01 | Aztrazeneca Ab | 2-anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos .proliferativos. |
| US8263595B2 (en) | 2007-08-31 | 2012-09-11 | Merck Serono Sa | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CA2706578A1 (en) | 2007-11-27 | 2009-06-04 | Cellzome Limited | Amino triazoles as pi3k inhibitors |
| WO2009155121A2 (en) | 2008-05-30 | 2009-12-23 | Amgen Inc. | Inhibitors of pi3 kinase |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| WO2010092015A1 (en) | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
| NZ594508A (en) | 2009-02-13 | 2013-12-20 | Fovea Pharmaceuticals | [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors |
| US8729082B2 (en) | 2009-04-29 | 2014-05-20 | Bayer Intellectual Property Gmbh | Substituted imidazoquinoxalines |
| TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
| EP2473498A1 (en) | 2009-09-04 | 2012-07-11 | Bayer Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
| EP2343295A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
| EP2343294A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| JP5824464B2 (ja) | 2010-01-15 | 2015-11-25 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | γセクレターゼ調節物質としての新規置換トリアゾール誘導体 |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| TWI541243B (zh) | 2010-09-10 | 2016-07-11 | 拜耳知識產權公司 | 經取代咪唑并嗒 |
| HUE025496T2 (en) | 2011-04-21 | 2016-04-28 | Bayer Ip Gmbh | Triazolopyridine derivatives |
| UA112096C2 (uk) * | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
| US9512126B2 (en) | 2012-03-14 | 2016-12-06 | Bayer Intellectual Property Gmbh | Substituted imidazopyridazines |
| NZ703020A (en) * | 2012-07-10 | 2017-08-25 | Bayer Pharma AG | Method for preparing substituted triazolopyridines |
| AR096469A1 (es) * | 2013-06-06 | 2015-12-30 | Bayer Pharma AG | Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas |
| JP2016527193A (ja) * | 2013-06-07 | 2016-09-08 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換トリアゾロピリジン |
| MX2015017011A (es) * | 2013-06-10 | 2016-04-25 | Bayer Pharma AG | Compuestos nuevos para el tratamiento del cancer. |
| AU2014280354A1 (en) * | 2013-06-11 | 2015-12-03 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer comprising a Mps-1 kinase inhibitor and a mitotic inhibitor |
-
2014
- 2014-06-06 MX MX2015017119A patent/MX2015017119A/es unknown
- 2014-06-06 HU HUE14728949A patent/HUE033131T2/en unknown
- 2014-06-06 WO PCT/EP2014/061779 patent/WO2014198647A2/en active Application Filing
- 2014-06-06 DK DK14728949.0T patent/DK3008062T3/en active
- 2014-06-06 EP EP14728949.0A patent/EP3008062B1/en active Active
- 2014-06-06 US US14/897,951 patent/US9586958B2/en not_active Expired - Fee Related
- 2014-06-06 ES ES14728949.0T patent/ES2626790T3/es active Active
- 2014-06-06 MA MA38654A patent/MA38654B1/fr unknown
- 2014-06-06 AU AU2014280356A patent/AU2014280356A1/en not_active Abandoned
- 2014-06-06 LT LTEP14728949.0T patent/LT3008062T/lt unknown
- 2014-06-06 EA EA201600002A patent/EA201600002A1/ru unknown
- 2014-06-06 SG SG11201509858QA patent/SG11201509858QA/en unknown
- 2014-06-06 JP JP2016518941A patent/JP2016526534A/ja active Pending
- 2014-06-06 PT PT147289490T patent/PT3008062T/pt unknown
- 2014-06-06 SI SI201430219A patent/SI3008062T1/sl unknown
- 2014-06-06 CN CN201480040729.XA patent/CN105377848A/zh active Pending
- 2014-06-06 AP AP2015008898A patent/AP2015008898A0/xx unknown
- 2014-06-06 CA CA2914745A patent/CA2914745A1/en not_active Abandoned
- 2014-06-06 RS RS20170534A patent/RS56034B1/sr unknown
- 2014-06-06 PE PE2015002605A patent/PE20160156A1/es not_active Application Discontinuation
- 2014-06-06 TN TN2015000545A patent/TN2015000545A1/en unknown
- 2014-06-06 KR KR1020167000270A patent/KR20160019492A/ko not_active Application Discontinuation
- 2014-06-06 PL PL14728949T patent/PL3008062T3/pl unknown
- 2014-06-11 AR ARP140102239A patent/AR096585A1/es unknown
- 2014-06-11 UY UY0001035610A patent/UY35610A/es not_active Application Discontinuation
-
2015
- 2015-11-30 IL IL242847A patent/IL242847A0/en unknown
- 2015-12-03 ZA ZA2015/08868A patent/ZA201508868B/en unknown
- 2015-12-09 PH PH12015502746A patent/PH12015502746A1/en unknown
- 2015-12-11 NI NI201500176A patent/NI201500176A/es unknown
- 2015-12-11 CU CUP2015000176A patent/CU20150176A7/es unknown
- 2015-12-11 CR CR20150659A patent/CR20150659A/es unknown
- 2015-12-11 CL CL2015003605A patent/CL2015003605A1/es unknown
- 2015-12-11 DO DO2015000299A patent/DOP2015000299A/es unknown
-
2016
- 2016-08-29 HK HK16110219.6A patent/HK1221955A1/zh unknown
-
2017
- 2017-05-12 HR HRP20170717TT patent/HRP20170717T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103561A1 (es) | Fenilpiridinas herbicidas | |
| AR123048A2 (es) | Moduladores de p2x7 | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR088781A1 (es) | Compuestos antimicrobianos y metodos para prepararlos y utilizarlos | |
| AR103252A1 (es) | Compuestos de quinazolina | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR105101A1 (es) | Derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
| AR102948A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3 | |
| AR095326A1 (es) | Heterociclos tricíclicos como inhibidores de la proteína bet | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR091023A1 (es) | Inhibidores del nampt | |
| AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR098906A1 (es) | Derivados de tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| AR106604A1 (es) | Compuestos de criptoficina y productos conjugados, su preparación y su uso terapéutico | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR103934A1 (es) | Derivados de benzimidazoles como inhibidores de bromodominio | |
| AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
| AR098776A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| AR098492A1 (es) | Derivados de purina | |
| AR093504A1 (es) | 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos | |
| AR100775A1 (es) | Compuestos pesticidas y procedimientos relacionados con los mismos | |
| AR096585A1 (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
| AR090572A1 (es) | Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |